When was Kimer Med founded?

Kimer Med was founded in 2020 and raised its 1st funding round 4 years after it was founded.

Where is Kimer Med located?

Kimer Med is headquartered in Nelson, New Zealand.

How many employees does Kimer Med have?

As of May 31, 2026, the latest employee count at Kimer Med is 10.

Is Kimer Med a funded company?

Kimer Med is a funded company, having raised a total of $***** in its 1st and only funding round, a Series A round on Jun 10, 2024.

When was the latest funding round of Kimer Med?

Kimer Med's latest funding was a $***** Series A round on Jun 10, 2024, with participation from 0 investor.

Where does Kimer Med rank among its competitors?

Kimer Med ranks 126th amongst 291 active competitors, of which 78 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Ascletis, which secured $108M in Feb, 2026.

Who are the top competitors of Kimer Med?

Kimer Med's top competitors include HOOKIPA Pharma, Vaxart and Atea. Among them, Ascletis secured the most recent funding round in February, 2026.

Kimer Med - 2026 Company Profile, Funding & Competitors

Company Details

Biotechnology company focused on developing broad-spectrum antiviral drugs. The company has VTose Platform to develop antiviral compounds against different viruses, including Dengue and Zika.

Website: www.kimermed.co.nz/
Social

Key Metrics

Founded Year

2020

Location

Nelson, New Zealand

Stage

Series A

Total Funding

$4M in 1 round

Latest Funding Round

Series A, Jun 10, 2024, $*****

Ranked

126^th among 291 active competitors

Employee Count

10 as on May 31, 2026

Similar Companies

HOOKIPA Pharma & 356 more

View Kimer Med's full profile

Kimer Med has raised a total funding of $4M over 1 round.

Here is the list of recent funding rounds of Kimer Med:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 10, 2024	3634961	Series A	5252644	2830900	1276101	7443023

Access funding benchmarks and valuations. Sign up today!

View details of Kimer Med's funding rounds and investors

Kimer Med's employee count trend

Kimer Med has 10 employees as of May 26. Here is Kimer Med's employee count trend over the years:

Uncover Kimer Med's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Kimer Med include HOOKIPA Pharma, Vaxart and Atea. Here is the list of Top 10 competitors of Kimer Med, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	HOOKIPA Pharma 2011, Vienna (Austria), Public	Developer of immunotherapies for the treatment of infectious diseases and cancer	$134M	Sofinnova Partners, Forbion & 12 others	68/100
2nd	Vaxart 2004, San Francisco (United States), Public	Developer of therapeutic solutions for treating multiple infectious diseases	$58M	Quantum Technology Partners, Life Science Angels ... & 8 others	67/100
3rd	Atea 2014, Boston (United States), Public	Developer of therapeutics for viral diseases	$293M	GSA Capital Partners, Bain Capital & 18 others	67/100
4th	Leyden Labs 2020, Amsterdam (Netherlands), Series B	Developer of nasal sprays containing antibodies targeting respiratory viruses in the nasal mucosa	$257M	Google Ventures, Casdin Capital & 11 others	64/100
5th	Brii Biosciences 2018, San Francisco (United States), Public	Developer of biologics to treat hepatitis B infection	$415M	HongShan, Invesco & 7 others	63/100
6th	eradivir 2020, West Lafayette (United States), Series A	Developer of immunotherapies for the treatment of infectious diseases	$20.4M	Research Bridge Partners, National Science Foundation ... & 2 others	62/100
7th	Ascletis 2011, Hangzhou (China), Series B	Developer of small molecules for the treatment of multiple diseases	$255M	CBC Group, Goldman Sachs & 5 others	61/100
8th	Novan 2006, Morrisville (United States), Public	Developer of Nitric Oxide based therapeutics for dermatology disorders	$113M	Aspire Capital, Ligand Pharmaceuticals & 6 others	60/100
9th	Virica Biotech 2018, Ottawa (Canada), Series A	Developer of viral sensitizer technology therapeutics to treat viral infections	$11.6M	Dynamk Capital, Ontario Canada & 4 others	60/100
10th	Visterra 2007, Cambridge (United States), Acquired	Developer of monoclonal antibodies against infectious diseases	$116M	Lux Capital, Flagship Pioneering & 14 others	60/100
126th	Kimer Med 2020, Nelson (New Zealand), Series A	Biotechnology company focused on developing broad-spectrum antiviral drugs	$4M	-	35/100